Utomilumab (PF 05082566) is a humanized IgG2 antibody that targets the T-cell co-stimulatory receptor 4-1BB/CD137 and acts as a 4-1BB/CD137 agonist. It exhibits antitumor activity and may be used in the study of patients with advanced malignancies.

Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the treatment of B-cell chronic lymphocytic leukemia and rheumatoid arthritis.

Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5. It induces apoptosis in various tumor types through caspase activation and can be used to study advanced solid tumors.

Tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), is a TRAIL-R2 agonist with antitumor activity that induces apoptosis in cancer cells, and can be used to study pancreatic cancer.

Benufutamab (GEN1029) is an agonistic antibody targeting death receptor 5 (DR5) with anti-tumor activity, used in the study of solid tumors.

Drozitumab (PRO 95780) is a fully humanized antibody targeting the death receptor DR5 that shows anti-tumor activity against rhabdomyosarcoma, binds to the death receptor DR5 and induces apoptosis, and can be used in the study of triple-negative breast cancer.

Urelumab(BMS-66513) is a humanized IgG4 monoclonal antibody, often used as a CD137 agonist.Urelumab has potential antitumor activity, potentiating tumor cell killing by T-cells and natural killer cells, and enhancing the cytotoxicity of Rituximab.Urelumab has been used in the study of solid tumor-related diseases such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Urelumab can be used to study diseases associated with solid tumors such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Tilogotamab (GEN-1029) is an agonistic hexameric complex targeting two independent epitopes on DR5, used for studying multiple myeloma (MM).

Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist. Feladilimab binds to ICOS-expressing T cells, induces IFNγ, and increases PD-1/L1 expression. Feladilimab has anti-tumor activity and can be used to study cancer.

Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that specifically binds to human CD162 (PSGL-1). this binding leads to the downregulation and apoptosis of activated T cells, a mechanism currently in clinical development for the treatment of steroid-refractory acute graft-versus-host disease (GVHD), psoriasis, psoriatic arthritis, and ulcerative colitis.

Alomfilimab (KY-1044) is a humanized monoclonal antibody targeting the inducible co-stimulator receptor (ICOS). As a selective ICOS blockade, it manipulates ICOS expression heterogeneity on T-cell subtypes. It can be used to study tumors.

Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.

Cifurtilimab (SEA-CD40) is a humanised monoclonal antibody acting as a CD40 agonist. It enhances binding to activated FcγRIIIa, exhibiting anticancer activity for treating pancreatic cancer, advanced solid tumours, and lymphoma.

Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors.

Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.

Sotigalimab (APX 005) is a monoclonal antibody targeting CD40 with potential antitumor activity and can be used to study metastatic pancreatic cancer and melanoma.

Rosnilimab (ANB030) is a programmed cell death protein 1 (PD-1) agonist that can inhibit antigen-driven T cell proliferation, reduce the secretion of pro-inflammatory cytokines, and deplete CD4 and CD8 T cell populations characterized by high PD-1 expression, thereby enabling its use in the research of various inflammatory diseases such as colitis and rheumatoid arthritis.

Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS. It exhibits anti-tumor immune effects and can improve metastatic non-small cell lung cancer.

Peresolimab is a humanized immunoglobulin G1 kappa (IgG1-κ) monoclonal antibody designed to target the programmed cell death protein 1 (PD-1) receptor, and it potentially functions by stimulating physiological immune inhibitory pathways to restore immune homeostasis and maintain self-tolerance, which can be applied in the research of autoimmune conditions such as rheumatoid arthritis.

Vonlerolizumab(MOXR 0916) is a humanized IgG agonistic OX40-specific monoclonal antibody with potential antitumor activity for the study of tumors and immune diseases.

Mapatumumab (HGS-ETR1) is a fully human agonistic monoclonal antibody targeting TNF-related apoptosis-inducing ligand receptor 1, with anticancer activity, capable of inducing apoptosis in cancer cells.

Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody with antitumor activity, useful for studying advanced solid tumors.

Iluzanebart, a human monoclonal IgG1 antibody, functions as an agonist antibody for human TREM2 (hTREM2), thereby enhancing the survival and overall function of microglia through the activation of the TREM2 signaling pathway. Iluzanebart provides compensation for the loss of CSF1R function, and it can be employed as a research agent for adult-onset leukoencephalopathy associated with CSF1R (colony stimulating factor 1 receptor) (CSF1R-ALSP), thereby providing opportunities to model microglial dysfunction in neurodegenerative disorders.

Selicrelumab (RG-7876) is an antibody targeting CD40 with potential anti-tumor activity that induces changes in the tumor microenvironment in patients with resectable pancreatic cancer and may be used to study pancreatic cancer.